3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
118
Neoplasms
14
Neoplasm Metastasis
14
Multiple Endocrine Neoplasia Type 1
5
Advanced Breast Cancer
5
Prostatic Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Breast Cancer Metastatic
3
Recurrence
2
Lymphoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Solid Malignancies
1
Small Cell Lung Carcinoma
1
Sex Cord-Gonadal Stromal Tumors
1
Sarcoma, Endometrial Stromal
1
Postmenopausal Women With ER+ HER2- Primary Breast Cancer
1
Patient Acceptance of Health Care
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Lethal Congenital Contracture Syndrome 2
1
Hyperglycemia
1
Interventions
abemaciclib
1
Trastuzumab
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hormone Receptor Positive Breast Cancer
×
Fulvestrant
×
Clear all
NCT02675231
2024-11-26
monarcHER
Eli Lilly and Company
Phase 2
Completed
237 enrolled
25 charts